Process for making tablet using radiofrequency and lossy coated particles

Patent metadata

Field	Value
Publication number	US-9789066-B2
Application number	US-201514592176-A
Country	US
Kind code	B2
Filing date	Jan 8, 2015
Priority date	Jan 10, 2014
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

In one aspect the present invention features process for making a tablet comprising at least one pharmaceutically active agent, said method comprising the step of applying radiofrequency energy to a powder blend to sinter said powder blend into said tablet, wherein said powder blend comprises lossy coated particles and said at least one pharmaceutically active agent, wherein said lossy coated particles comprises a substrate that is at least partially coated with a lossy coating comprising at least one activator, wherein said substrate has a Q value of greater than 100 and said activator has a Q value of less than 75.

First claim

What is claimed is:

1. A process for making a tablet comprising at least one pharmaceutically active agent, said method comprising the step of applying radiofrequency energy to a powder blend to sinter said powder blend into said tablet, wherein said powder blend comprises lossy coated particles and said at least one pharmaceutically active agent, wherein said lossy coated particles comprises a substrate that is at least partially coated with a lossy coating comprising at least one activator, wherein said substrate has a Q value of greater than 100 and said activator has a Q value of less than 75 and wherein the surface of said lossy coated particle comprises said activator wherein the friability at 15 drops of the tablet is less than about 5%.

2. A process of claim 1 , wherein said activator has a Q value of less than 50.

3. A process of claim 2 , wherein said substrate has a Q value of greater than 200.

4. A process of claim 1 , wherein said substrate has a Q value of greater than 200.

5. A process of claim 1 , wherein said lossy coated particles have a Q value of greater than 100.

6. A process of claim 1 , wherein said powder blend has a Q value of greater than 100.

7. A process of claim 1 , wherein said powder blend comprises at least 20%, by weight, of said lossy coated particles.

8. A process of claim 1 , wherein said lossy coated particles comprise from about 0.1 to about 2%, by weight, of said at least one activator.

9. A process of claim 1 , wherein said lossy coated particle comprises from about 0.1% to about 3%, by weight, water.

10. A process of claim 1 , wherein said tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds.

11. The process of claim 1 , wherein said radiofrequency energy has a frequency of from about 13 MHz to about 40 MHz.

12. A process of claim 1 , wherein said tablets are formed within a tablet die.

13. A process of claim 1 , wherein said activator is a polymer selected from the group consisting of celluloses, hydrocolloids, polymethacrylates, polyvinyls, proteins, polysaccharides, and copolymers thereof.

14. A process of claim 1 , wherein said activator is hydroxypropylcellulose or hydroxyethylcellulose.

15. A process of claim 1 , wherein said substrate comprises a starch, a sugar alcohol, or a sugar.

16. A process of claim 1 , wherein said substrate comprises maltitol or mannitol.

17. A process of claim 1 , wherein said substrate comprises said pharmaceutically active agent.

18. A process of claim 1 , wherein said tablet further comprises a water scavenger.

19. A process of claim 1 , wherein said tablet further comprises a plasticizer.

20. The process of claim 1 wherein said at least one pharmaceutically active agent is contained within particles separate from the lossy coated particles.

21. The process of claim 20 wherein said separate particles comprising the pharmaceutically active agent comprise a taste masking coating.

22. The process of claim 1 wherein said tablet has an in vitro disintegration time of about 30 seconds or less when based on the United States Pharmacopeia USP 24 NF29.

23. A process for making a tablet comprising the step of applying radiofrequency energy to a powder blend to sinter said powder blend into said tablet, wherein said powder blend comprises lossy coated particles and separate particles comprising at least one pharmaceutically active agent, wherein said lossy coated particles comprise a substrate that is at least partially coated with a lossy coating comprising at least one activator, wherein the Q value of the activator is less than half the Q value of the substrate wherein the friability at 15 drops of the tablet is less than about 5%.

24. The process of claim 23 wherein said tablet has an in vitro disintegration time of about 30 seconds or less when based on the United States Pharmacopeia USP 24 NF29 and the friability at 15 drops of the tablet is less than about 5%.

25. The process of claim 24 wherein said substrate comprises a sugar alcohol, or a sugar and said activator comprises a polymer selected from the group consisting of celluloses, polyvinyls, polysaccharides, and copolymers thereof.

Assignees

• Johnson & Johnson Consumer Inc

Inventors

• Szymczak Christopher E
• Dave Vipul
• Mcnally Gerard P
• Cochran David B
• Koll Gregory
• Ulrich Stephen

Classifications

• A61K9/20

  Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title

• A61K9/00

  Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title

• B01J2/006

  Coating of the granules without description of the process or the device by which the granules are obtained (to prevent the granules sticking together B01J2/30) · CPC title

• A61K31/138

  Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title

• A61K31/137 Primary

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title